Clinical Trial Update: Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL) [Phase 3]

View source ↗

Summary

Phase 3 retreatment study of Galiximab plus Rituximab for follicular non-Hodgkin's lymphoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Galiximab (galiximab)
• Rituximab (rituximab)

Snippet

Sponsor: Biogen | Conditions: Lymphoma, Non-Hodgkin's | Phase 3 | Status: TERMINATED